Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Inflammatory Bowel Disease I: Introduction01:26

Inflammatory Bowel Disease I: Introduction

Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Near-infrared fluorescence cholangiography assisted laparoscopic cholecystectomy (FALCON): an international multicentre randomized controlled trial.

Surgical endoscopy·2023
Same author

[Prophylactic intubation of the lacrimal duct in chemoradiotherapy of the lacrimal sac].

Die Ophthalmologie·2021
Same author

New methodology to process shifted excitation Raman difference spectroscopy data: a case study of pollen classification.

Scientific reports·2020
Same author

Corrigendum to "Biochemical alterations in the Musculus triceps brachii and Musculus longissimus thoracis during early postmortem period in pigs" [Meat Science 152 (2019) 121-126].

Meat science·2019
Same author

Biochemical alterations in the Musculus triceps brachii and Musculus longissimus thoracis during early postmortem period in pigs.

Meat science·2019
Same author

Autofluorescence lifetime augmented reality as a means for real-time robotic surgery guidance in human patients.

Scientific reports·2019

Related Experiment Video

Updated: Jun 12, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

A claims-based Markov model for Crohn's disease.

D C Malone1, H C Waters, J Van Den Bos

  • 1University of Arizona College of Pharmacy, Tucson, 85721-0202, USA. malone@pharmacy.arizona.edu

Alimentary Pharmacology & Therapeutics
|May 25, 2010
PubMed
Summary

Healthcare costs for Crohn's disease patients rise with disease severity. While severe-fulminant Crohn's disease has low transition probabilities, its cost per quality-adjusted life year (QALY) is high.

More Related Videos

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

A Rat Graft Rejection Model of Intestinal Transplantation with Exteriorized Ileostomy for Longitudinal Prognosis Assessment
08:25

A Rat Graft Rejection Model of Intestinal Transplantation with Exteriorized Ileostomy for Longitudinal Prognosis Assessment

Published on: June 10, 2025

Related Experiment Videos

Last Updated: Jun 12, 2026

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

A Rat Graft Rejection Model of Intestinal Transplantation with Exteriorized Ileostomy for Longitudinal Prognosis Assessment
08:25

A Rat Graft Rejection Model of Intestinal Transplantation with Exteriorized Ileostomy for Longitudinal Prognosis Assessment

Published on: June 10, 2025

Area of Science:

  • Gastroenterology
  • Health Economics
  • Chronic Disease Management

Background:

  • Crohn's disease (CD) is a chronic inflammatory bowel disease typically diagnosed in early adulthood.
  • Effective management of CD requires understanding its long-term health care cost implications.

Purpose of the Study:

  • To evaluate the health care costs associated with Crohn's disease.
  • To determine the cost per quality-adjusted life year (QALY) for different disease severity states in Crohn's disease.

Main Methods:

  • A Markov model was developed using administrative claims data from 40,063 adult patients with at least two CD claims and three years of continuous enrollment.
  • Disease states were defined as remission, mild-moderate, moderate-severe, and severe-fulminant based on American College of Gastroenterology criteria.
  • Transition probabilities between states were calculated, and costs were derived from paid claims, with QALY utilities sourced from literature.

Main Results:

  • The study analyzed 420,773 cycles across disease states: remission (46.8%), mild-moderate (10.5%), moderate-severe (31.5%), and severe-fulminant (11.2%).
  • Costs per QALY varied significantly by disease state and sex: remission ($2896), mild-moderate ($8428 male, $8426 female), moderate-severe ($11,518 male, $22,633 female), and severe-fulminant ($69,277 male, $69,412 female).

Conclusions:

  • Health care costs for Crohn's disease patients demonstrably increase with disease severity.
  • Despite low transition probabilities, the severe-fulminant disease state presents a high cost per QALY, highlighting the economic burden of advanced Crohn's disease.